CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Apr. 02, 2022	Apr. 03, 2021	Mar. 28, 2020
Cash Flows from Operating Activities:
Net income	$ 43,375	$ 79,469	$ 76,526
Non-cash items:
Depreciation and amortization	97,747	84,287	110,289
Impairment of assets	7,953	21,969	50,599
Share-based compensation expense	24,359	25,516	20,454
Gain on divestiture and sale of assets	(9,603)	(32,812)	(8,083)
Contingent consideration expense	10,461	0	0
Deferred tax benefit	5,013	(19,866)	(6,958)
Amortization of deferred financing costs	3,404	564	596
(Benefit) provision for losses on inventory	(861)	7,860	(2,904)
Other non-cash operating activities	5,592	1,500	2,260
Change in operating assets and liabilities:
Change in accounts receivable	(34,974)	44,121	18,863
Change in inventories	24,307	(38,909)	(84,721)
Change in prepaid income taxes	2,870	(3,822)	1,480
Change in other assets and other liabilities	(15,022)	(4,650)	(2,876)
Change in accounts payable and accrued expenses	7,642	(56,422)	(17,308)
Net cash provided by operating activities	172,263	108,805	158,217
Cash Flows from Investing Activities:
Capital expenditures	(96,509)	(37,040)	(48,758)
Proceeds from divestiture	10,642	44,587	9,808
Proceeds from sale of property, plant and equipment	2,022	1,815	16,774
Acquisitions	(2,500)	(434,804)	(35,000)
Net cash used in investing activities	(86,345)	(425,442)	(57,176)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(17,500)	(21,875)	(13,125)
Net (decrease) increase in short-term loans	0	(60,000)	45,000
Proceeds from issuance of convertible notes	0	500,000	0
Purchase of capped call related to convertible notes	0	(47,400)	0
Transaction costs paid in connection with convertible notes issuance	0	(13,457)	0
Contingent consideration payments	(4,791)	0	0
Proceeds from employee stock purchase plan	4,209	4,013	3,369
Proceeds from exercise of stock options	2,338	6,217	8,647
Share repurchases	0	0	(175,000)
Other financing activities	(5)	(46)	(99)
Net cash (used) in provided by financing activities	(15,749)	367,452	(131,208)
Effect of exchange rates on cash and cash equivalents	(2,978)	4,179	(1,873)
Net Change in Cash and Cash Equivalents	67,191	54,994	(32,040)
Cash and Cash Equivalents at Beginning of Year	192,305	137,311	169,351
Cash and Cash Equivalents at End of Year	259,496	192,305	137,311
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,187	7,824	12,545
Income taxes paid	24,298	12,487	11,507
Transfers from inventory to fixed assets for placement of Haemonetics equipment	51,800	9,287	14,479
Tenant improvement allowances excluded from capital expenditures	$ 0	$ 0	$ 5,660